Specific clinical phenotype (posterior variant, logopenic variant, frontal variant, and Down's syndrome variant of AD) PLUS in vivo evidence of AD pathology (abnormal CSF biomarker, amyloid PET, genetic evidence in PSEN1, PSEN2, or APP). This evidence concerns the gene APP and Alzheimer disease.